Trials / Terminated
TerminatedNCT02112942
Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects
A Phase I Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated. Antiviral activity will also be assessed in HCV-infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDX21459 | |
| DRUG | Matching Placebo |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2014-04-14
- Last updated
- 2016-01-26
Source: ClinicalTrials.gov record NCT02112942. Inclusion in this directory is not an endorsement.